Skip to Content


In the US, Opdivo (nivolumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Colorectal Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Urothelial Carcinoma.

US matches:

UK matches:

Ingredient matches for Opdivo


Nivolumab is reported as an ingredient of Opdivo in the following countries:

  • France
  • Germany
  • Switzerland
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.